Quimioterapia en dosis altas para niños y adultos jóvenes con rabdomiosarcoma en estadio IV
Información
- DOI:
- https://doi.org/10.1002/14651858.CD006669.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 08 diciembre 2010see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Cáncer infantil
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Conception and design: Rick Admiraal, Jasmijn Kobes, Leontien CM Kremer, Gianni Bisogno, Johannes HM Merks.
Data collection and analysis: Rick Admiraal, Marcel van der Paardt, Leontien CM Kremer, Johannes HM Merks.
Manuscript writing: Rick Admiraal, Marcel van der Paardt, Jasmijn Kobes, Leontien CM Kremer, Gianni Bisogno, Johannes HM Merks.
Sources of support
Internal sources
-
Dutch Cochrane Center, Netherlands.
External sources
-
No source of support, Not specified.
Declarations of interest
Gianni Bisogno is the first author of one of the included studies and co‐author of this review.
Acknowledgements
We would like to thank Leon Bax for translating a Japanese article, and Edith Leclercq (Trial Search Co‐ordinator) for developing the search strategy and providing the titles/abstracts from the three electronic databases, Elvira van Dalen, MD PhD, as substitute Co‐ordinating Editor and the editorial base of the Cochrane Childhood Cancer Group for their support. The editorial base of the Cochrane Childhood Cancer Group is funded by Kinderen Kankervrij (KIKA).
Version history
| Published | Title | Stage | Authors | Version |
| 2010 Dec 08 | High‐dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma | Review | Rick Admiraal, Marcel van der Paardt, Jasmijn Kobes, Leontien CM Kremer, Gianni Bisogno, Johannes HM Merks | |
| 2007 Jul 18 | High dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma | Protocol | Rick Admiraal, Marcel van der Paardt, Jasmijn Kobes, Leontien CM Kremer, Gianni Bisogno, Johannes HM Merks | |
Differences between protocol and review
Outcome measure 'median survival': since this is an infrequently used concept and is rarely, if ever, reported we only included event‐free survival and overall survival as survival outcome measures.
Types of studies: as no randomised controlled trials were found, in addition to controlled clinical trials, we also searched for prospective non‐controlled clinical trials including at least 20 naive metastatic rhabdomyosarcoma patients.
Since there were no randomised controlled trials included, and different aspects of the quality of the studies should be reported, we had to adjust the quality assessment criteria described in the original protocol. We assessed the quality of the articles (i.e. risk of selection bias, attrition bias, detection bias and performance bias) using various items.
